CAMBRIDGE, Mass.--(BUSINESS WIRE)--X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking and increase the ability for T-cells to track and destroy cancer, today announced the appointment of Nancy Lurker as the Chair of the Company’s Board of Directors. Ms. Lurker is an accomplished biopharmaceutical industry leader with more than 25 years of strategic, management and operational experience across all aspects of drug development and commercialization.
